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Abstract
Background: Inadequate extracellular conditions can adversely affect the environment of the ER and impinge on the
maturation of nascent proteins. The resultant accumulation of unfolded proteins activates a signal transduction pathway,
known as the unfolded protein response, which serves primarily to protect the cell during stress and helps restore
homeostasis to the ER.
Principal Findings: Microarray analysis of the unfolded protein response in a human medulloblastoma cell line treated with
thapsigargin revealed that, in addition to known targets, a large number of proangiogenic factors were up-regulated. Real-
Time PCR analyses confirmed that four of these factors, VEGFA, FGF2, angiogenin and IL8, were transcriptionally up-
regulated in multiple cell lines by various ER stress inducers. Our studies on VEGFA regulation revealed that XBP-1(S), a UPR-
inducible transcription factor, bound to two regions on the VEGFA promoter, and analysis of XBP-1 null mouse embryonic
fibroblasts revealed that it contributes to VEGFA expression in response to ER stress. ATF4, another UPR-inducible
transcription factor, also binds to the VEGFA gene, although its contribution to VEGFA transcription appeared to be fairly
modest. We also found that VEGFA mRNA stability is increased in response to UPR activation, via activation of AMP kinase,
demonstrating that increased mRNA levels occur at two regulatory points. In keeping with the mRNA levels, we found that
VEGFA protein is secreted at levels as high as or higher than that achieved in response to hypoxia.
Conclusions and Significance: Our results indicate that the UPR plays a significant role in inducing positive regulators of
angiogenesis. It also regulates VEGFA expression at transcriptional, post-transcriptional and post-translational levels and is
likely to have widespread implications for promoting angiogenesis in response to normal physiological cues as well as in
pathological conditions like cancer.
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Introduction
Changes in the extracellular environment of a cell can adversely
affect the normal homeostasis of the endoplasmic reticulum (ER),
which disrupts the folding and processing of secretory pathway
proteins. The resulting accumulation of unfolded proteins in the
ER increases the demands for molecular chaperones and folding
enzymes and activates a signal transduction cascade known as the
unfolded protein response (UPR) [1]. This multi-component signal
transduction pathway is largely cytoprotective; serving to decrease
the detrimental effects of accumulated unfolded proteins by
increasing molecular chaperones that bind to them, decreasing
protein synthesis to limit the accumulation, and finally increasing
the degradative capacity of the cell to eliminate them. However if
normal homeostasis is not restored during prolonged stress
conditions, the UPR can induce apoptosis in these cells in order
to protect the organism [1,2]. In mammalian cells, the UPR is
controlled by three resident ER transmembrane proteins that
‘‘sense’’ ER stress and activate signals to downstream elements;
Ire-1, PERK and ATF6. Ire-1 is an ER localized transmembrane
protein, which has a kinase and endoribonuclease domain in its
cytosolic tail. On sensing ER stress, Ire-1 is phosphorylated in
trans, which in turn activates its endonuclease domain leading to
the excision of 26 bases from the X-box binding protein (XBP-1)
transcript [3]. The resulting frame shift encodes a fully active
transcription factor XBP-1(S), which up-regulates expression of a
number of resident ER proteins that contribute to folding or
degradation of unfolded or misfolded proteins [4,5]. In addition to
Ire-1 signaling, mammalian cells also transiently inhibit cap-
dependent protein translation and arrest cells in the G1 phase of
the cell cycle through activation of the PKR-like ER kinase
(PERK) [6,7]. Contrary to this global inhibition in protein
translation occurring in PERK-activated cells, synthesis of the
ATF4 transcription factor is increased during ER stress [6]. ATF4
transactivates expression of a number of genes including CHOP
[8], a pro-apoptotic protein, and GADD34 [9], which reverses the
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survival protein, thus contributing to the balance between survival
and death signals. Lastly, activation of ATF6 results in its
translocation to the Golgi and cleavage by the S1P and S2P
proteases to release the cytosolically oriented active transcription
factor that up-regulates expression of XBP-1, as well as folding
enzymes and ER chaperones, such as PDI and BiP [11,12].
In addition to protecting cells during physiological and chemical
conditions that adversely affect protein folding in the ER, there is
increasing evidence to show that the UPR also plays an important
role in normal development and physiology. This includes liver
development [13], plasma cell differentiation [14,15], bone
development [16,17], and normal pancreatic homeostasis [18].
Mice that are null for either XBP-1 [13] or its upstream activator
Ire1a [19,20,21,22] die at day E12.5 due to hepatoinsufficiency. In
both cases, this was later confirmed to be due to an inability to
produce XBP-1(S), a major regulator of hepatic development. In
addition to liver, pancreas, and muscle, XBP-1(S) is also highly
expressed in the placenta [19], and Ire1a null embryos show
evidence of placental abnormalities. To determine the role of Ire1
in this tissue, a recent study generated mice lacking Ire1a by
crossing Ire1a
+/2 mice with Mox2
+/Cre transgenic mice [19]. Mox2
is ubiquitously expressed except in the labyrinthine trophoblasts of
the placenta. This allowed Ire1-deficient embryos to be produced
that have normal levels of Ire1 in the placenta [19]. This study
revealed that loss of Ire1a in the placenta led to decreased vascular
endothelial growth factor (VEGFA) production, which is a major
inducer of angiogenesis, thereby resulting in severe dysfunction of
this highly vascularized tissue.
Angiogenesis refers to the sprouting, migration and remodeling
of existing blood vessels [23] and plays an important role in a
number of normal physiological processes including embryonic
development, wound healing, and the female reproductive cycle. It
also plays a role in several pathological conditions including
ischemia and cancer. Angiogenesis is regulated by a fine balance
between factors that stimulate the formation of new blood vessels
and those that inhibit it [24,25]. Proangiogenic factors such as
VEGF, fibroblast growth factors (FGFs), platelet derived growth
factors (PDGFs), and IL8 are released by cancer cells experiencing
decreased oxygen and nutrient supplies [26,27,28]. These factors
act as ligands that bind to specific receptors on endothelial cells,
causing them to proliferate and to release matrix metalloprotei-
nases that degrade the extracellular matrix, allowing them to
migrate toward the angiogenic stimulus in order to establish new
blood vessels [26]. The predominant and best studied proangio-
genic factor is VEGFA, a homodimeric heparin binding
glycoprotein that is produced in several isoforms due to alternative
splicing. The different isoforms of VEGFA (206, 189, 165, 145 and
121) have varying expression patterns and contrasting properties
[29]. Of these VEGF165 is the predominant and best characterized
isoform, and plays an important role in mediating angiogenesis
[30]. All VEGF isoforms are synthesized and processed in the
endoplasmic reticulum (ER) and transported through the secretory
pathway [26,31].
The HIF (hypoxia inducible factor) pathway is the best
characterized cellular stress pathway that leads to the up-
regulation of proangiogenic factors in response to inadequate
oxygen delivery [32]. HIF-1 and HIF-2 are heterodimeric
transcription factors consisting of an oxygen-labile a subunit and
a constitutively expressed b subunit. Hypoxia stabilizes the a
subunit, thereby activating the HIF complex, which in turn binds
to the promoters of target genes such as VEGF and other
proangiogenic factors and transactivates them [33]. Prolonged
hypoxia can also increase VEGFA mRNA stability leading to
further increases in VEGFA production [34]. In addition to the
role of the HIF signaling pathway in up-regulating VEGF
expression, several recent studies demonstrate that the UPR also
contributes to VEGF transcription [35] and protein processing in
the ER [36]. Using microarray analysis, we found that in addition
to VEGFA a large number of proangiogenic factors were up-
regulated by UPR inducers. The up-regulation of several of these
factors by ER stress was as robust as, or even greater than, that
achieved with hypoxia. We found that two UPR-regulated
transcription factors bound directly to the VEGFA promoter in
response to ER stress and contributed to its transcription. In
addition, activation of AMP kinase stabilized the VEGFA
transcripts, further contributing to VEGFA mRNA levels. Our
finding that a number of regulators of angiogenesis are a target of
the UPR argues that this physiological process should be added to
the growing list of normal homeostatic and developmental
processes that this stress pathway controls.
Results
UPR activation results in the transcriptional up-regulation
of a number of proangiogenic factors
We wished to characterize the UPR in a solid tumor cell line
that could ultimately be used in xenograft studies to ensure that
this stress response was fully active and that all branches were
intact. To do so, we treated Daoy, a human medulloblastoma cell
line with thapsigargin, a Ca
2+ ATPase inhibitor and potent
inducer of the UPR, and performed genome-wide microarray
analyses. Overall, we identified 1069 probe sets with differential
expression after either 3 or 8 hours of thapsigargin treatment
compared to untreated cells. Further analysis of this data
confirmed significant enrichment of the expected UPR target
genes, including ER chaperones, folding enzymes, and proteins
involved in ER associated degradation (ERAD), as well as the
transcription factors that are known to up-regulate them in
response to ER stress. In addition to UPR targets, somewhat
unexpectedly, gene ontology analysis revealed a significant
enrichment of genes associated with the regulation of angiogenesis.
A total of 185 genes on the array are annotated as being associated
with angiogenesis. As many of these encode endothelial cell-
specific proteins or cell surface receptors on endothelial cells, we
limited our further analysis to the 33 genes that are secreted
proteins or transcription factors that either positively or negatively
regulate angiogenesis. Of the 19 genes that are characterized as
positive regulators of angiogenesis, 13 showed a greater than 2-fold
increase in expression in at least one time point after thapsigargin-
treatment (Table 1). Additionally expression of one negative
regulator of angiogenesis, vasohibin (VASH1) was decreased with
ER stress. These data suggest that regulating angiogenesis is likely
to be a major function of the UPR.
Comparison of UPR inducers with hypoxia in the
up-regulation of proangiogenic factors
To confirm the induction of proangiogenic factors by the UPR,
we treated cell lines with UPR inducers and compared the
magnitude of their induction to that achieved with conditions that
activate the HIF pathway using quantitative Real-Time PCR
(qRT-PCR) (Figure 1). We confirmed by western blot analyses that
CoCl2 and the level of hypoxia (1% O2) used in our experiments
induced HIF1a and BNIP3, its downstream target, but did not
induce UPR targets. Importantly, the UPR inducing agents did
not activate the HIF signaling pathway (Figure S1). Thus the
conditions we used in our analysis allowed us to specifically
activate these two stress pathways independently. Five different
UPR Induces Angiogenic Factors
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12521cell lines were treated with a variety of UPR inducers (e.g.,
tunicamycin, thapsigargin, and no glucose) and with two different
inducers of the HIF pathway (e.g., CoCl2 and 1% oxygen) for
24 hours, and the induction of four of the best characterized
proangiogenic factors: VEGFA, bFGF, angiogenin and IL8 was
measured. We also confirmed that downstream UPR target genes
like CHOP and BiP mRNA were up-regulated by ER stress in each
of the cell lines tested (Figure S2). As expected, all four factors were
up-regulated by hypoxic conditions, although the magnitude
varied dramatically between cell lines, largely due to differences in
their basal levels of synthesis (Figure S3). When UPR inducers
were used, we found that in many cases the induction of the four
proangiogenic factors was nearly as high as or even higher than
that achieved with hypoxia, although there were some interesting
differences. Hypoxia was a strong inducer of VEGFA mRNA in the
NB1691 neuroblastoma cell line, while ER stress had little effect
on VEGFA levels. Conversely ER stress induced VEGFA in the
NIH3T3 fibroblast line, but hypoxia did not (Figure 1A). Similarly
ER stress induced FGF2 expression greater than hypoxia in the
Daoy line, whereas neither stress condition stimulated its
production in the C6 and NIH3T3 cell lines, perhaps due to the
high levels of basal expression of FGF2 in these two lines
(Figure 1C). In keeping with the microarray data, angiogenin
was modestly induced in the Daoy cell line and the NB1691 line,
but in the other three lines there was very little effect with either
hypoxia or ER stress inducers (Figure 1B), again in keeping with
higher basal levels in these lines. Finally, increases in human-
specific IL8 expression were much more dramatic with ER stress
than with hypoxia in all three human cell lines (Figure 1D).
UPR activation increases VEGFA mRNA stability via AMPK
In this study we focused on determining the mechanism by
which the UPR regulates VEGFA expression, as VEGFA is the best
characterized stimulator of angiogenesis and represents a thera-
peutic target for treating cancer as well as several ischemic,
infectious and inflammatory disorders [37]. Additionally, we
favored this target because in most of the lines we examined,
including mouse cells, VEGFA was induced to higher levels with
ER stress than with hypoxia. We chose the C6 cell line for these
experiments, because it had a low basal expression of VEGF which
was potently induced by ER stress, previous studies used this line
to study VEGF gene regulation by hypoxia, and this line was used
in xenograft studies to determine the role of ORP150/GRP170 in
VEGF processing and secretion. VEGFA mRNA levels increase in
response to hypoxic conditions via a combination of an enhanced
transcription iaat early time points coupled with an increase in the
stability of the mRNA at later times [38]. To investigate whether
UPR activation might also increase VEGFA mRNA stability, we
examined the turnover of VEGFA mRNA under control and
various stress conditions (Figure 2A). Cells were pretreated with
hypoxia or two different UPR inducers and then incubated with
actinomycin D to inhibit further transcription. In control cells the
low level of basal transcripts were rapidly degraded in keeping with
previous studies [34,39]. For all three stress inducers, there was a
reproducible increase in VEGFA mRNA at 30 minutes after
adding actinomycin D, which is compatible with an increase in
transcription occurring before the inhibitor takes effect. We found
that although hypoxic conditions led to an initial increase in
VEGFA levels, the mRNA was rapidly degraded. This is
consistent with a previous report using C6 cells, which showed
that hypoxia had no significant effect on the half-life of VEGFA
mRNA until much later time points [38]. When cells were
pretreated with the two UPR inducers, we found that after the
initial burst in VEGFA transcripts they decayed significantly slower
than in control or hypoxia-treated cells. (Figure 2A), arguing that
ER stress leads to increased VEGFA mRNA stability at relatively
early times in the response.
The increase in VEGFA mRNA stability observed after
prolonged exposure to hypoxic conditions is due to the binding
of a hypoxia-inducible protein complex, such as HuR, to the ARE
(adenylate-uridylate rich elements) region in the 3’UTR region of
VEGFA mRNA [34]. Additionally, stress activated protein kinases
such as AMPK, p38MAPK, JNK, and PI3K have been implicated
in increasing VEGFA mRNA stability through their action on the
AU rich region of the 3’UTR [40,41,42,43]. We used a variety of
kinase inhibitors to determine if any of their targets might play a
role in increasing the stability of VEGFA mRNA during ER stress.
Table 1. UPR activation enhances expression of proangiogenic factors.
Fold change Tg treated
Gene Symbol Gene Name Angiogenic Effect 3 hour 8 hour
ANG Angiogenin Positive 2.4 8.1
ANGPT2 Angiopoietin-2 Positive 22.6 2.2
CTGF Connective tissue growth factor Positive 2.2 1.4
EPAS1 Endothelial Pas domain protein 1 (HIF2a) Positive 1.8 2.6
EREG Proepiregulin Positive 2.3 6.3
FGF2 Fibroblast growth factor-2 Positive 1.5 3.1
F3 Thromboplastin Positive 2.9 1.6
IL1A Interleukin-1 a Positive 4.4 10.8
IL6 Interleukin-6 Positive 4.8 7
IL8 Interleukin-8 Positive 54.25 27.9
KLF5 Kruppel-like factor 5 Positive 2.6 3.5
TGFB2 Transforming growth factor beta-2 Positive 4.1 2.9
VEGFA Vascular endothelial growth factor A Positive 1.7 2.7
VASH1 Vasohibin Negative 21.3 23
doi:10.1371/journal.pone.0012521.t001
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an AMP kinase inhibitor, there was a significant reduction in
VEGFA transcripts (Figure 2C), suggesting that this kinase played a
role in the UPR-induced stabilization of VEGFA. Activation of
AMPK by ER stress was confirmed by western blotting, as was the
efficacy of its inhibitor, Compound C (Figure 2B). We also co-
incubated UPR activated cells with inhibitors of the PI3 and JUN
kinases, but found that they had no affect on VEGFA mRNA levels
in response to UPR activation (data not shown). As an additional
control, the effect of the AMPK inhibitor on VEGFA mRNA levels
was examined in cells pre-treated with hypoxia for 6 h (Figure 2C),
which was previously shown to be not long enough to stabilize
VEGFA transcripts [38]. Unexpectedly, we found that VEGFA
stability was actually increased in hypoxia treated cells that we
incubated with Compound C, although we do not understand the
basis for this effect. To verify that the effects of this inhibitor was
specifically on VEGFA mRNA stability and did not alter
transcription of the VEGFA gene, we treated cells with the various
combinations of kinase inhibitor and stress inducers and examined
heteronuclear VEGFA RNA (hnRNA) levels (Figure 2D), which
can be used as a measure of transcription. We found that there was
no indication that this inhibitor affected VEGFA transcription, thus
Figure 1. Up-regulation of proangiogenic factor mRNA by the UPR and hypoxia. Daoy, NB1691, SKNAS, C6 and NIH3T3 cells were treated
with 100 mM CoCl2,1 %O 2 hypoxia (Hy), 2.5 mg/ml tunicamycin (Tm), 1 mM thapsigargin (Tg), or no glucose media (No Glu) for 24 hours. RNA was
extracted for qRT-PCR analysis and mRNA fold induction relative to the untreated control sample, which was set to 1, was determined for (A) VEGF
(white bars) (B) angiogenin (striped bars) (C) FGF2 (chequered bars) and (D) IL8 (grey bars). Experiments were performed in triplicate (values are
mean 6 SD).
doi:10.1371/journal.pone.0012521.g001
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which apparently is due to the activation of the AMP kinase.
UPR activation increases the transcription of VEGFA
Our analysis of VEGFA hnRNA in the experiment described
above revealed that the unprocessed hnRNA levels were higher in
cells treated with thapsigargin or no glucose than in control cells.
This suggested that VEGFA might also be transcriptionally
regulated in response to ER stress. Prior to using hnRNA levels
as a measure of the transcription rate, we first confirmed that the
splicing of VEGFA mRNA was not significantly affected by UPR
activation. Cells were pretreated for 6 hours with the indicated
stressors, and actinomycin D was added to inhibit further
transcription. Heteronuclear RNA was then measured at the
indicated time points. We found that VEGFA hnRNA decreased at
a fairly similar rate in control and stress activated cells through at
least eight hour of treatment, arguing that these stresses did not
dramatically affect splicing up to this point (Figure 3A). Therefore,
the measurement of VEGFA hnRNA could be used as an
indication of the transcription rate of this gene in response to
UPR activation (Figure 3B). Cells incubated in media containing
no glucose, increased VEGFA transcription to a much greater
extent than either thapsigargin or hypoxia at all time points
measured, which is in keeping with the 30 minute time point in
Figure 2A. Thapsigargin was as good as or better than hypoxia at
inducing VEGFA transcription throughout the course of the
experiment. Thus, the increased transcription rate, coupled with
the stabilization of VEGFA transcripts, accounts for the higher
steady state level of VEGFA mRNA in response to thapsigargin
compared to hypoxia in this cell line (Figure 1A). Although the
transcription rate of VEGFA appeared to be the highest in the
presence of no glucose, this is not reflected in the steady state levels
after 24 hours of treatment (Figure 1A), which may be due to some
inhibition of splicing occurring at later time points (Figure 2A).
XBP-1 binds to two regions in the rat VEGFA promoter
To identify potential binding sites for various UPR-inducible
transcription factors, we analyzed the human, mouse and rat
VEGFA promoters using the computer programs rVista and
TRANSFAC (Figure S4). In addition to HIF sites, the promoters
of all three species have a number of potential binding sites for the
UPR-induced transcription factors XBP-1 and ATF4, whereas
only the mouse promoter has a single ATF6 site. We first assessed
whether XBP-1(S) bound to any of the five potential sites in the rat
promoter in response to ER stress using a chromatin immuno-
precipitation (ChIP) assay, since the C6 rat glioma was used for
both the mRNA stability and transcription assays. Indeed, XBP-
1(S) could be detected at two different sites (i.e., one at ,1.9 kb
and one at ,5.2 kb up-stream of the transcription start site) in
response to both thapsigargin and no glucose treatment
(Figure 4B). We were unable to detect XBP-1(S) binding to the
remaining three potential sites in these cells upon UPR activation,
Figure 2. UPR activation stabilizes VEGF mRNA via AMPK. (A) C6 cells were pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-
square), thapsigargin (Tg-triangle), or no glucose media (No Glu-cross) for 6 hours. Actinomycin D (5 mg/ml) was added to the various cultures to
block further transcription. At the indicated times, total RNA was extracted and subjected to qRT-PCR to determine VEGF mRNA levels. The mean
values of data from duplicate experiments are presented (6 SD). (B) C6 cells were either left untreated or treated as indicated in the figure in the
presence or absence of Compound C for 9 hours or 14 hours. Western blot analysis was performed on cell lysates to determine levels of p-AMPK.
Hsc70 was used as loading control. (C–D) C6 cells were pretreated with different stress inducers for 6 hours as indicated. No inhibitor (black) or
compound C (AMPK inhibitor- white) was added to the cells as indicated for an additional 8 hours. Total RNA was extracted for qRT-PCR to determine
VEGF mRNA (C) and VEGF hnRNA (D) levels. Experiments were performed in triplicate (values are mean 6SD).
doi:10.1371/journal.pone.0012521.g002
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antiserum used to immunoprecipitate the chromatin could not
gain access to these sites. As a positive control, we showed that
XBP-1 binds to the ERdj3 promoter (Figure 4C), as documented
previously [44]. We detected XBP-1(S) protein in ER stressed but
not in untreated C6 cell lysates that were used for the chromatin
immunoprecipitation assays (Figure 4D).
XBP-1 mediates increased expression of VEGFA following
ER stress
To determine the contribution of XBP-1 to the up-regulation of
VEGFA transcription, we made use of XBP-1 wild-type (XBP-1 wt)
and null (XBP-1 ko) mouse embryonic fibroblasts (MEFs).
Examination of these cells by western blotting confirmed that no
XBP-1(S) protein could be detected in the XBP-1 null cells in
response to UPR induction (Figure 4E). Next we compared the fold
induction of both VEGFA hnRNA (Figure 4F) and VEGFA mRNA
(Figure 4G) in both cell lines after treating with three different ER
stress inducers; thapsigargin, no glucose media, and homocysteine.
Our qRT-PCR analysis in the XBP-1 wild-type MEFs demonstrat-
ed an ,10 fold increase in VEGFA transcription rate after 8 h of
either thapsigargin or homocysteine treatment (Figure 4F); whereas
no glucose media was a relatively poor inducer of VEGFA
transcription in this cell line, perhaps in keeping with the reduced
amount of XBP-1(S) produced by this stress condition (Figure 4E).
The transcription rate was highest at 8 h for both thapsigargin and
homocysteine treatment, demonstrating that its induction is not
sustained during UPR activation in the wild-type MEFs as was
observed in the C6 cell line. This is mirrored in the total mRNA
transcripts, which were also higher at 8 hrs of stress induction
(Figure 4G).When the XBP-1null cellsweresimilarlyexamined,we
found that there was little or no increase in VEGFA transcription
with any of the treatments, suggesting that XBP-1 played a major
role in the up-regulation of VEGFA in response to ER stress.
However, closer analysis of the VEGFA hnRNA data from the two
cell lines revealed that the untreated XBP-1 wild-type MEFs had a
lower basal level of VEGFA hnRNA than the null cells, (Figure S5).
Hence, the exact contribution of XBP-1 in up-regulating VEGFA
was somewhat complicated by the differences in basal transcription
rates between the two lines.
ATF4 contributes to up-regulation of VEGFA expression
following UPR activation
Inspection of the human, mouse and rat VEGFA promoters also
revealed several potential ATF4 binding sites (Figure 5A and S4).
To determine if any of these sites was occupied by ATF4 in
response to ER stress, we performed ChIP assays in ATF4 wild-
type (ATF4 wt) and null (ATF4 ko) MEFs. We were unable to
detect binding of ATF4 to any of the seven potential sites upstream
of the transcription start site in response to thapsigargin treatment
(data not shown). However, we did detect stress-inducible binding
of ATF4 to a site at position +900 relative to the transcription start
site in the wild-type ATF4 MEFs but not in the ATF4 null MEFs
(Figure 5B). Similar to the wild-type MEFs, we were unable to
detect ATF4 binding to any of the five upstream regions in the rat
promoter (Figure S6). However, unlike the human and mouse
promoter, there does not appear to be a site downstream of the
transcription start site in the rat promoter that corresponds to the
one used in murine cells. To determine the contribution of ATF4
to VEGFA transcription in response to UPR stress inducers, we
analyzed steady state VEGFA hnRNA (Figure 5C) and mRNA
(Figure 5D) levels in ATF4 wild-type and null MEFs. Although the
fold increase in total VEGFA mRNA in response to ER stress was
not very dramatic in either the wild-type or null cells, it was
consistently slightly higher in the ATF4 wt MEFs.
ATF6 does not significantly contribute directly to VEGFA
expression
Although there were no obvious potential ATF6 binding sites in
the human or rat VEGFA promoters, there was one potential
ATF6 binding site in the mouse VEGFA gene at +1.4 kb relative to
the transcription start site. Thus, we also examined the potential
contribution of ATF6 in regulating VEGFA transcription. qRT-
PCR analysis of VEGFA mRNA in ATF6 wild-type (ATF6 wt) and
Figure 3. UPR activation increases VEGF transcription rate. (A) C6 cells were pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-
square), thapsigargin (Tg-triangle), or no glucose media (No Glu-cross) for 6 hours as indicated. Actinomycin D (5 mg/ml) was added to block further
transcription. At the indicated times, total RNA was extracted and subjected to qRT-PCR to determine the kinetics of the disappearance of VEGF
hnRNA in control and stressed cells. (B) C6 cells were untreated (NT-black), treated with 1% O2 (Hy-grey), thapsigargin (Tg-striped) or no glucose
media (No Glu-white) for the indicated times. Total RNA was extracted, and VEGF hnRNA was quantitated by qRT-PCR. Experiments were performed
in triplicate (values are mean 6SD).
doi:10.1371/journal.pone.0012521.g003
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a significant role in up-regulating VEGFA expression in response to
either tunicamycin treatment or incubation in media lacking
glucose (Figure 6A). However, in response to thapsigargin
treatment there was a modest, albeit significant, increase in total
VEGFA mRNA in ATF6 wild-type cells compared to null cells.
The difference between the stresses in inducing VEGFA transcripts
was a bit puzzling. Because XBP-1 transcription is regulated by
ATF6 and our analysis revealed that XBP-1(S) binds to the VEGFA
promoter, we examined XBP-1(S) levels in the two lines in
response to the various UPR inducers. Western blot analysis
revealed a more dramatic increase in XBP-1(S) protein levels in
the thapsigargin-treated ATF6 wild-type cells compared to the null
cells (Figure 6B), whereas there was no obvious difference between
the two tunicamycin-treated cell lines. Somewhat surprisingly,
media lacking glucose did not induce XBP-1(S) in either cell line.
These data imply that the higher levels of VEGFA mRNA observed
in the thapsigargin-treated wild-type cells compared to the null
cells might be partly due to a more robust increase in XBP-1(S)
levels in the wild-type cells.
Figure 4. XBP-1 binds to two regions in the rat VEGF promoter in response to ER stress and contributes to increasing VEGF
transcription rate. (A) Potential XBP-1 sites in the rat VEGF promoter. (B) Cross-linked chromatin from C6 cells that were untreated (NT),
thapsigargin-treated (Tg), or incubated in no glucose media (No Glu) for 8 hours were immunoprecipitated with anti-XBP-1 or with a control
antiserum (anti-BiP). Ten-fold serial dilutions of precipitated chromatin and input controls were used for PCR amplification. (C) As a positive control,
primers spanning the XBP-1 binding region on the ERdj3 promoter were used to PCR amplify the anti-XBP-1 precipitated chromatin (D) XBP-1(S)
protein levels were detected in C6 cells treated with Tg and No Glu media using Western blot analysis. (E) XBP-1 wild-type (black) or null (white) MEFs
were untreated (NT), thapsigargin-treated (1 mM), treated with media lacking glucose (No Glu) or homocysteine-treated (10 mM) for 14 hours. Cell
lysates were prepared and XBP-1(S) was detected by western blot analysis. (F-G) Cells were treated as in (E) and total RNA from the indicated samples
was subjected to qRT-PCR to quantify VEGF hnRNA (F)o rVEGF mRNA (G) at the indicated time points. RNA levels were expressed relative to the
control untreated samples for each line, which was set to 1. Experiments were performed in triplicate (values are mean 6 SD).
doi:10.1371/journal.pone.0012521.g004
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Lastly, we measured the effects of the UPR and hypoxia
signaling pathways on VEGFA protein levels in the cells
(Figure 7A) and in the culture supernatant (Figure 7B). We could
readily detect VEGFA in lysates obtained from cells treated with
all three of the UPR inducers but not in cells cultured in the
hypoxia chamber or treated with CoCl2 (Figure 7A), in spite of the
fact that hypoxia increased VEGFA mRNA in this cell line to about
the same level as tunicamycin treatment. A faster migrating
unglycosylated VEGFA was detected in cells treated with
tunicamycin and no glucose media, as these stressors are known
to inhibit protein glycosylation. In spite of our inability to detect
VEGFA in hypoxia treated cells, when media from cells treated
with the various UPR inducers and hypoxia were examined, we
readily detected an increase in VEGFA secretion with all stressors
(Figure 7B). However, the combination of cell-associated and
secreted VEGFA with each of the treatments is not consistent with
the mRNA levels. For example, although VEGFA mRNA levels
were highest in cells treated with thapsigargin compared to any of
the other four stress conditions (Figure 1A), it was not secreted as
well from these cells as from tunicamycin or no glucose treated
cells. Additionally, although both hypoxia and tunicamycin
treatment resulted in similar increases in VEGFA transcripts,
tunicamycin treatment resulted in the secretion of greater
quantities of VEGFA (Figure 7B). Previous studies demonstrated
that the ER stress-inducible chaperone GRP170/ORP150 plays
an important role in VEGFA processing and secretion in the C6
cells [36]. Thus we examined the effects of the various stressors on
GRP170 induction at both the mRNA and protein levels. We
found that tunicamycin and no-glucose were potent inducers of
GRP170 mRNA (Figure 7C) and protein (Figure 7A), whereas
thapsigargin only modestly induced this chaperone and hypoxia
had almost no effect on GRP170 levels. Thus the relatively high
levels of VEGFA secretion in tunicamycin and no-glucose treated
cells are consistent with the increased GRP170 levels in these cells.
Discussion
Angiogenesis is a normal physiological process that is important
for embryonic development as well as wound healing [25,37]. It is
carefully controlled by a large number of secreted factors that bind
to receptors on endothelial cells, as well as negative regulators that
inhibit angiogenesis through direct effects on endothelial cells or
indirect effects on growth factor mobilization and activation
[24,37]. Recent studies have shown that VEGFA, one of the major
proangiogenic factors, is a target of the UPR. Our microarray
analysis of UPR targets in thapsigargin-treated Daoy cells
confirmed VEGFA induction, but unexpectedly revealed that there
Figure 5. ATF4 contributes to VEGF expression and binds to the mouse promoter in a stress inducible manner. (A) Potential ATF4 sites
in the mouse VEGF promoter (B) Cross-linked chromatin from ATF4 wild-type or null MEFs that were untreated (NT) or thapsigargin-treated (Tg) for
6 h was immunoprecipitated with anti-ATF4 or with a control antiserum (anti-BiP). Precipitated chromatin and input controls were used for PCR
amplification. (C–D) ATF4 wild-type (black) or null (white) were cultured in normal media (NT), thapsigargin-treated (1 mM), or tunicamycin-treated
(2.5 mg/ml) for 3 and 6 hours. Total RNA from the indicated samples was subjected to qRT-PCR, and VEGF hnRNA (C)o rVEGF mRNA (D) levels were
determined and represented as described above. Experiments were performed in triplicate (values are mean 6 SD).
doi:10.1371/journal.pone.0012521.g005
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of angiogenesis, including secreted proangiogenic factors, cyto-
kines, and transcription factors that positively regulate proangio-
genic factors, as well as a decrease in one negative regulator of
angiogenesis. This argues that the regulation of angiogenesis is
likely to be an important function of the UPR. Of note, the UPR
was a potent inducer of IL8 expression in multiple cells lines
(Figure 1D). A recent report demonstrated that addition of IL8 to
endothelial cells can induce VEGFA mRNA and protein levels in a
HIF1a-independent manner that requires NFkB activation [45].
Because ER stress also leads to NFkB activation, it is conceivable
that IL8 contributes to VEGF induction during UPR activation in
some of our lines. However, although the NB1691 cell line
potently up-regulates IL8, it does not induce VEGFA mRNA levels
on UPR activation. The reason for this is not known as other UPR
targets are clearly activated in this line and VEGF is induced by
hypoxia.
The major function of the UPR is thought to be restoring or
maintaining ER homeostasis in response to an inadequate or toxic
environment that adversely affects this organelle and its ability to
fold and assemble proteins. Thus it is perhaps not surprising that
one mechanism for doing this would be to increase the supply of
Figure 6. ATF6 does not significantly contribute to VEGF expression. (A) ATF6 wild-type (black) or null (white) MEFs were untreated (NT),
thapsigargin-treated (1 mM), tunicamycin-treated (2.5 mg/ml) or treated with media lacking glucose (No Glu) for 6 hours. Total RNA from the indicated
samples was subjected to qRT-PCR, and the VEGF mRNA levels were determined. (B) XBP-1(S) was detected using western blot analysis on cell lysates
from ATF6 wild-type and null MEFs that were untreated or treated as indicated. Experiments were performed in triplicate (values are mean 6 SD).
doi:10.1371/journal.pone.0012521.g006
Figure 7. UPR activation increases VEGF protein levels and secretion. (A) C6 cells were left untreated or treated as indicated for 24 hours.
Western blot analyses on cell lysates were performed to detect VEGF protein levels. Hsc70 was used as a loading control. (B) Conditioned media from
untreated and treated cells was analyzed for VEGF secretion by ELISA. (C) Total RNA from the indicated samples was subjected to qRT-PCR, and
GRP170 mRNA levels were determined and expressed relative to the control cells.
doi:10.1371/journal.pone.0012521.g007
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can be delivered and waste and other toxic products could be
taken away. In keeping with this possibility, physiological processes
like wound healing require increased vascularization [46], and
studies show evidence of UPR activation in the affected cells [47].
Similarly the placenta must be highly vascularized in order to
supply adequate quantities of oxygen and nutrients to the
developing fetus and to remove toxic waste products. Although
there are not data to demonstrate that the UPR is normally
activated in the developing trophoblasts, a recent report found that
Ire1 was required for normal placenta vascularization and fetal
development [19]. This aspect of the UPR might also be used in
pathological conditions like cancer [48,49] and ischemia [50] to
stimulate angiogenesis, as in both cases there is evidence of UPR
activation [2].
We focused our further analysis on VEGFA because it is the
best characterized and most potent endothelial growth factor that
promotes angiogenesis and is a target of cancer therapy. Recently
a study has shown that VEGFA mRNA can be up-regulated in
cultured cells by the UPR inducers, thapsigargin and tunicamycin
[35]. We confirmed the role of the UPR in up-regulating VEGFA
expression in various cell lines and also shown that the UPR is a
much better inducer of VEGFA mRNA than hypoxia in a number
of transformed and non-transformed cell lines, further arguing that
this represents a normal function of the UPR. We next focused our
attention on the mechanism of increased VEGFA mRNA
expression via UPR and hypoxia signaling pathways using the
C6 rat glioma cell line. The UPR increases VEGFA mRNA
stability as well as the transcription rate of the gene to an even
greater extent than that achieved with hypoxia. Several stress-
activated protein kinases, including AMPK, have been reported to
increase VEGFA mRNA stability. The activation of the AMP
kinase has been linked to low glucose levels that result in
diminished ATP production [51]. In addition to nutrient
deprivation, other metabolic stresses such as hypoxia, oxidative
stress and exercise lead to activated AMPK [52]. In DU145
prostate carcinoma cells cultured without glucose, JNK was shown
to act upstream of AMPK pathway to increase VEGFA mRNA
stability [42]. However, in our analysis of the C6 cells treatment
with SP600125 the JNK inhibitor had no effect on VEGFA mRNA
stability, whereas treatment with the AMPK inhibitor enhanced its
stability in response to both thapsigargin and no glucose,
suggesting that conventional UPR inducing agents can also
activate AMPK.
Next, we assessed the importance of the major UPR-induced
transcription factors (i.e., XBP-1(S), ATF4 and ATF6) in mediating
VEGFA transcription. Most recently, Ghosh R et al [35], dem-
onstrated that Ire1 null MEFs, which cannot splice XBP-1 and
induce its downstream targets, have a significant reduction in
VEGFA mRNA expression compared to the Ire1 wild-type cells
when treated with thapsigargin. Using a VEGFA-promoter-
luciferase assay and chromatin immunoprecipitation they also
showed that exogenously supplied XBP-1 can bind to the VEGFA
promoter and up-regulate VEGFA mRNA expression. Our studies
reveal direct binding of endogenous XBP-1 to two distinct sites in
the rat VEGFA promoter in response to ER stress. Our qRT-PCR
data showed an increase in the VEGFA transcription rate in the
XBP-1 wild-type cells treated with various UPR inducers
compared with the XBP-1 null cells. The increased levels of
VEGFA mRNA observed in the wild-type cells was primarily due
to an increase in the transcription rate of the gene, since these
inducers had little effect on the stability of VEGFA transcript in this
cell line (data not shown). Previously published data showed that
tumors derived from U87 cells expressing an Ire1 dominant
negative construct developed smaller tumors with decreased
vascularization as compared to tumors from control cells [53].
In addition to this study, two independent reports have also
demonstrated a role for XBP-1 in tumor establishment, growth
and angiogenesis [54,55]. However, the former study found that
when XBP-1 deficient cells are treated with extreme hypoxia/
anoxia (pO2,0.02%) in vitro, there is no defect in secretion of the
proangiogenic factors, VEGFA and bFGF, as compared to wild-
type cells. As these extremely low O2 conditions would be
expected to induce both the UPR and the HIF pathways, it is
conceivable that in the absence of XBP-1, HIF1a and 2a are able
to compensate. In support of this possibility, there are HIF binding
sites in close proximity with the XBP-1 ‘‘A’’ site occupied in
response to ER stress (Figure 4B) in all three species. As tumor
cells, ischemic tissue, and wounds are likely to activate both types
of stress pathways, it will be important to understand the overlap
and relative contribution of each factor in a physiological setting.
Several studies have demonstrated a role for ATF4 in mediating
expression of VEGFA in response to various stimuli such as
homocysteine [56], arsenite [57], oxidized phospholipids [58], and
osteopontin [59]. Arsenite is an oxidative stressor that stimulates
ATF4 binding to the VEGFA promoter in a human retinal pigment
epithelial cell line at position +1767 relative to the transcription
start site [57]. Similar observations by another group demonstrat-
ed that ATF4 binds to the same AARE site in the VEGFA
promoter when a human umbilical vein endothelial cell line was
stimulated with oxidized phospholipids [58]. These results are in
accordance with data published by Ghosh et al reporting a PERK-
ATF4 dependent up-regulation of VEGFA expression. Using both
PERK and ATF4 null MEFs treated with thapsigargin, they
showed that VEGFA mRNA levels were decreased as compared to
the corresponding wild-type MEFs, and demonstrated binding of
ectopically expressed ATF4 to the VEGFA promoter in cells
treated with thapsigargin. Using ChIP assays, we confirmed that
ATF4 contributes to VEGFA transcription and furthermore
demonstrated that endogenous ATF4 binds to a region
,+0.9 kb downstream of the transcription start site in mouse
cells when treated with a UPR inducer.
Lastly, our data suggests that ATF6 does not play a significant
role in directly mediating VEGFA mRNA expression. We observed
a modest increase in VEGFA mRNA in the ATF6 wild-type MEFs
compared to the ATF6 null cells when treated with thapsigargin
but not the other stressors. This induction was most likely due to
an increase in the XBP-1(S) protein levels observed only in
thapsigargin-treated ATF6 wild-type cells. The VEGFA promoter-
reporter assay performed by Ghosh et al, showed that over-
expression of the transcription factor ATF6 increases luciferase
activity ,6 fold compared to empty vector. The reporter construct
used in this assay was derived by inserting ,1 kb of the sequence
upstream of the mouse VEGFA transcription start site, in front of
the luciferase gene. Using two different programs to identify
transcription factor binding sites in this region of the mouse
VEGFA promoter, we were unable to identify any potential ATF6
sites. However, this region contains a potential binding site for
XBP-1, which this group reported could bind to ectopically
expressed XBP-1 using ChIP assays. However, we were unable to
detect binding of endogenous XBP-1 to this same site (data not
shown).
In addition to the role of UPR-inducible transcription factors in
mediating VEGFA expression, there are data showing that the
stress inducible ER chaperone ORP150/GRP170 plays a role in
post-translational processing/secretion of VEGFA [36]. Ectopic
expression of ORP150 in C6 cells increased VEGFA secretion,
whereas decreasing ORP150 levels with an antisense construct
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tumors arising from the antisense ORP150 C6 glioma transfec-
tants demonstrate an initial phase of growth comparable to the
wild-type glioma cells which was followed by marked regression
and decreased angiogenesis within 8 days. Our analysis of VEGFA
secretion in C6 cells revealed that although hypoxia and
tunicamycin lead to similar increases in VEGFA mRNA, that
more VEGFA was secreted from the tunicamycin treated cells,
which had higher levels of ORP150/GRP170 mRNA and protein
levels. This correlation is further underscored by the finding that
although thapsigargin was the strongest inducer of VEGFA mRNA,
it caused a less robust up-regulation of GRP170 and less VEGFA
was secreted from thapsigargin treated cells than from either
tunicamycin or no-glucose treated cells.
In conclusion, using microarray analysis we found a significant
up-regulation of a large proportion of positive regulators of
angiogenesis in response to ER stress and verified four of these
using qRT-PCR assays. Our studies revealed that in some cell lines
UPR activation enhanced VEGFA mRNA and protein expression
more potently than hypoxia and that this was achieved through a
combination of transcriptional as well as post-transcriptional
mechanisms. Thus, the UPR is likely to be an important regulator
of angiogenesis in normal physiological settings as well as
pathological conditions like cancer and ischemia and may synergize
with the well-studied HIF pathway activated by hypoxia.
Materials and Methods
Cell Culture and Stress Induction
Daoy human medulloblastoma cell line [60], C6 rat glioma cell
line [61], XBP-1 wild-type and null MEFs, ATF6 wild-type and
null MEFs, and NIH3T3 mouse fibroblasts were maintained in
DMEM supplemented with 10% fetal bovine serum, 2 mM
glutamine and 1% antibiotic-antimycotic at 37uC in a 5% CO2
incubator. NB1691 and SKNAS human neuroblastoma cell lines
were cultured in RPMI 1640 supplemented with 10% fetal bovine
serum and 2 mM glutamine. Primary wild-type and ATF4 null
MEFs were propagated in cell culture as previously described [9].
Cells were plated and left untreated (NT) or treated with
thapsigargin (Tg, 1 mM), tunicamycin (Tm, 2.5 mg/ml), homocys-
teine (HCys, 10 mM), CoCl2 (100 mM), media lacking glucose (No
Glu) (DMEM cat.no.11966-GIBCO and RPMI cat. no.11879-
GIBCO), or cultured in a hypoxia chamber containing 1% O2 for
the indicated periods of time.
mRNA and hnRNA Quantification by qRT-PCR
Total RNAwasextractedusing the RNeasyQiagenmini-prepkit
according to the manufacturer’s protocol. RNA samples were
subjected to qRT-PCR, and reactions were done in duplicate using
a TaqMan One-Step PCR Master Mix kit. Amplification of the
corresponding genes was achieved using specific primers and probe
set and measured continuously using an ABI 7900 HTI Detection
System. Where indicated, VEGF hnRNA was measured using
qRT-PCR primers and probe acrossintron 1 and exon 2, for the rat
gene and across exon 3 and intron 3, for the mouse gene. The signal
obtained for measuring both, mRNA and hnRNA, was compared
relative to 18S rRNA internal control. A recent study detected
down-regulation of ribosomal RNA by ER stress [62]. However, in
our study the 18S rRNA cycle threshold (Ct) values obtained by
qRT-PCR remained relatively unchanged in the presence of ER
stress arguing that 18S rRNA levels were not changing with the
conditions used. Table S1 contains a list of primers and probes used
in this study. The value for untreated cells was set to 1 and the value
for the various treatments was presented as a fraction of this
number. In the case of wild-type and null cells, the untreated value
for each cell type was set to 1 unless otherwise indicated.
mRNA Stability Assay
C6 cells were pre-incubated in normal complete media, media
containing thapsigargin or no glucose, or in a hypoxia chamber for
6 hours. Actinomycin D (5 mg/ml- Sigma Aldrich) was added to
each test set, and the cells were reincubated for the indicated
times. Total RNA was extracted and VEGF mRNA was analyzed
by qRT-PCR.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was performed
using a ChIP kit (Upstate Biotechnology) according to the
manufacturer’s instructions. Briefly, cells were incubated for the
indicated times with or without different stress inducers. Formal-
dehyde was then added (final concentration, 1%), and cells were
incubated for 10 minutes at room temperature to stabilize DNA-
protein interactions. Cross-linking was stopped by the addition of
glycine (final concentration, 0.125 M). Cell extracts were sonicated
with a Branson Sonifier 250 (VWR) for 5 bursts at 10 seconds each
at 20% power output to shear DNA to 1 kb or less. Extracts from
10
7 cells were incubated overnight with antibodies against ATF4
generously provided by Dr. David Ron (University of Cambridge,
U.K.), rabbit anti-XBP-1(S) polyclonal antiserum (Santa Cruz
Biotechnology sc-7160X) or rabbit anti-BiP polyclonal antiserum
[63], which served as a negative control. Two percent of the extract
volume was removed before immunoprecipitation and served as
input control. DNAfragmentsfrom immunoprecipitated complexes
and input controls were released by heating at 65uC overnight and
purified using the PCR purification kit (QIAquick, Qiagen)
according to the manufacturer’s protocol. Purified immunoprecip-
itated DNA and input DNA were then analyzed by PCR. Table S2
contains a list of primers used in this study.
Western Blotting
For Western blotting cells were lysed in Nonidet P-40 lysing
buffer (50 mM Tris-HCl (pH7.5), 150 mM NaCl, 0.5% Nonidet
P-40, and 0.5% deoxycholic acid) for 30 minutes on ice. The
proteins were electrophoresed under reducing conditions, trans-
ferred to a PVDF membrane and probed with the indicated
primary antibodies: Rabbit anti-XBP-1(S), rabbit anti-ATF4, goat
anti-Hsc70, and goat anti-Lamin B1 were purchased from Santa
Cruz Biotechnology, mouse anti-HIF1a and mouse anti-BNIP3
from Abcam, and rabbit anti-phosho-AMP kinase from Cell
Signaling. Rabbit anti-CHOP has been described previously [8].
Isolation of nuclear and cytosolic fraction for detecting HIF1a by
Western blotting was performed as previously described [64]. Blots
were incubated with the appropriate HRP-conjugated secondary
antibody, and proteins were visualized using the Pierce enhanced
chemiluminescent substrate (Thermo Scientific).
Microarray Gene Expression Analysis
Total RNA (5–10 mg) was processed according to the Affymetrix
eukaryote one-cycle target labeling protocol (http://www.affymetrix.
com/support/technical/manual/expression_manual.affx) at the
Hartwell center microarray core at St Jude Children’s Research
Hospital. Biotin-labeled cRNA (15 mg) was hybridized overnight
at 45uC to the human HG-U133 Plus 2.0 GeneChip array, which
interrogates more than 54,000 human transcripts and ESTs.
After staining and washing, arrays were scanned and expression
values summarized using the MAS5 algorithm as implemented in
the GCOS v1.4 software (Affymetrix, Santa Clara, CA). Signals
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of 500. Detection calls (Present, Absent and Marginal) were
determined using the default parameters of the software. Signal
values were log2-transformed prior to analysis. Differential
expression between thapsigargin-treated and untreated cells was
determined from two independent experiments using the Local
Pooled Error t-test(1) (S-Plus 6.2, TIBCO, Palo Alto, CA). False
discovery estimates were calculated as described [65]. Hierarchi-
cal clustering was performed using the Spotfire Decision Site 9.0
software (TIBCO). Probe set annotations were obtained from the
Affymetrix website (http://www.affymetrix.com/analysis/index.
affx). Gene ontology and network analysis was performed using
Metacore from GeneGo Inc. (St. Joseph, MI). All data is MIAME
compliant, and the raw data has been deposited in GEO, a
MIAME compliant database, accession number: GSE21979.
Statistical analysis
All results are expressed as mean values plus or minus SD from
triplicate measurements performed in 2 to 4 independent
experiments producing similar results.
Supporting Information
Figure S1 HIF signaling pathways are not activated by UPR
inducers nor are UPR targets activated by hypoxia. C6 cells were
treated with 100 mM CoCl2, 1% O2 hypoxia (Hy), 2.5 mg/ml
tunicamycin (Tm),1 mMthapsigargin (Tg),ornoglucose media(No
Glu) for 24 hours. Western blot analysis was performed to measure
(A) BNIP3 and CHOP proteinlevels in the cytosolicfraction. Hsc70
was used as a loading control. (B) HIF1a levels were determined in
the nuclear fraction using Lamin B1 as control and CHOP levels
were determined in the cytosolic fraction using Hsc70 as control.
Found at: doi:10.1371/journal.pone.0012521.s001 (0.21 MB TIF)
Figure S2 UPR inducing agents up-regulate CHOP and BiP
mRNA. Daoy, C6, NB1691, SKNAS and NIH3T3 cells were
treated with 100 mM CoCl2, 1% O2 hypoxia (Hy), 2.5 mg/ml
tunicamycin (Tm), 1 mM thapsigargin (Tg), or no glucose media
(No Glu) for 24 hours. RNA was extracted for qRT-PCR analysis
and expression levels of CHOP mRNA (black bars) and BiP
mRNA (white bars) were determined relative to 18SrRNA.
Experiments were performed in triplicate (values are mean 6 SD).
Found at: doi:10.1371/journal.pone.0012521.s002 (0.26 MB TIF)
Figure S3 Basal levels of proangiogenic factor expression in
different cell lines. Daoy, NB1691, SKNAS, C6 and NIH3T3 cells
were treated with 100 mM CoCl2, 1% O2 hypoxia (Hy), 2.5 mg/
ml tunicamycin (Tm), 1 mM thapsigargin (Tg), or no glucose
media (No Glu) for 24 hours. RNA was extracted for qRT-PCR
analysis and basal levels of expression for (A) VEGF (B) angiogenin
(C) FGF2 and (D) IL-8 were determined relative to 18SrRNA.
Experiments were performed in triplicate (values are mean 6 SD).
Found at: doi:10.1371/journal.pone.0012521.s003 (0.21 MB TIF)
Figure S4 Potential binding sites of UPR downstream tran-
scription factors in human, mouse and rat VEGF promoter. Two
online softwares, rVista and TRANSFAC were used to screen
potential binding sequences of transcription factors, XBP-1 (cyan),
ATF4 (green), HIF (red) and ATF6 (yellow) in a 9 kb upstream
promoter region of human, mouse and rat VEGF gene.
Found at: doi:10.1371/journal.pone.0012521.s004 (0.20 MB TIF)
Figure S5 Basal levels of VEGF hnRNA in XBP-1 wild-type
and null MEFs. XBP-1 wild-type MEFs (black) and null MEFs
(white) were untreated (NT), Thapsigargin-treated (1 mM), treated
with media lacking glucose (No Glu) or Homocysteine-treated
(HCys, 10 mM) for 8 h and 14 h. Total RNA from the indicated
samples was subjected to qRT-PCR and VEGF hnRNA/18S
ratios were determined relative to the control untreated samples.
Found at: doi:10.1371/journal.pone.0012521.s005 (0.08 MB TIF)
Figure S6 ATF4 does not appear to bind to the rat VEGF
promoter. (A) Potential ATF4 sites in the rat VEGF promoter. (B)
Cross-linked chromatin from C6 cells that were untreated (NT),
Thapsigargin-treated (Tg), or incubated in No glucose media (No
Glu) for 8 h were immunoprecipitated with anti-ATF4. As positive
control, primers spanning the ATF4 binding region on the CHOP
promoter were used to PCR amplify the anti-ATF4 precipitated
chromatin (C) CHOP protein levels were determined using
Western blot analysis in the C6 cells that were used in the ChIP
assays.
Found at: doi:10.1371/journal.pone.0012521.s006 (0.23 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0012521.s007 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0012521.s008 (0.03 MB
DOC)
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